Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 31, 2021 07:00 ET | Source: Provectus Biopharmaceuticals Inc.

Provectus Biopharmaceuticals Announces Publication of Australian Compassionate Use Patients Treated with PV-10® Immunotherapy for In-Transit Melanoma Lesions

46% complete response of patients at Melanoma Institute AustraliaFifth published study of in-transit melanoma lesion treatment with single-agent PV-1026-50% complete response (52-86% overall response)...
December 14, 2017 06:00 ET | Source: Provectus Biopharmaceuticals Inc.

PROVECTUS BIOPHARMACEUTICALS RECEIVES THIRD CANCER COMBINATION THERAPY PATENT FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE

– Protection expands coverage for combinations of intralesional PV-10 with checkpoint inhibitors for multiple solid tumor cancers – KNOXVILLE, TN, Dec. 14, 2017 (GLOBE NEWSWIRE) -- Provectus...